Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST)　― A Prospective Multicenter Study ―

Key Points

• VTE recurrence occurred in a small percentage of cancer patients, reflecting the effectiveness of rivaroxaban.
• The study reports a low incidence of worsening VTE among patients across multiple centers in Japan.
• This prospective multicenter study assessed the safety of rivaroxaban in the cancer-VTE population.
• Findings imply that rivaroxaban may be a reliable option for managing venous thromboembolism in cancer patients.